In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...
EXXUA is a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of major depressive disorder (MDD) in adults. EXXUA is also being developed for other psychiatric disorders ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) announces the launch of ...
An extended-release oral tablet formulation of ketamine has shown promise for treatment-resistant depression (TRD) results of a phase 2 proof-of-concept study suggest. In the trial, twice weekly ...
Attention Deficit Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental disorder leading to impairments in learning and behaviour. ADHD affects approx. 3-5% of adults and 5-9% of children and ...
Zituvimet XR is supplied in 3 extended-release tablet strengths. The Food and Drug Administration (FDA) has approved Zituvimet XR (sitagliptin and metformin hydrochloride) extended-release tablets as ...
Auvelity (dextromethorphan/bupropion) is a prescription drug that’s used to treat depression. The drug comes as an extended-release tablet. It’s usually taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback